Dr. Gary Michelson Receives Albert B. Sabin Humanitarian Award

WASHINGTON, D.C. — March 25, 2015 — The Sabin Vaccine Institute (Sabin) will present the Albert B. Sabin Humanitarian Award to Gary Michelson, MD, a distinguished orthopedic spinal surgeon and inventor, in recognition of his extraordinary philanthropy and commitment toward the control and elimination of neglected tropical diseases (NTDs) through high-level advocacy and vaccine research and development. He will be honored today at a private event with Sabin’s executive leadership, Board of Trustees and key members of the scientific community in Houston, Texas.

India Launches Massive Public Health Campaign to Eliminate Lymphatic Filariasis

WASHINGTON, D.C. — January 14, 2015 — India was certified polio-free in 2014. Today, the country has its sights set on another public health victory: the elimination of lymphatic filariasis, a neglected tropical disease (NTD) that threatens nearly half of its population. To meet this ambitious goal, the Indian Ministry of Health & Family Welfare (MOHFW) has launched one of the largest public health campaigns in India’s history to provide more than 400 million people with free medication that could protect them from lymphatic filariasis.

Coalition against Typhoid Awarded Funding to Advance Surveillance of Typhoid and Paratyphoid

WASHINGTON, D.C. — December 16, 2014 — The Sabin Vaccine Institute, through the Coalition against Typhoid (CaT) Secretariat, announced today that it has received an award of approximately US$ 5 million from the Bill & Melinda Gates Foundation to support the establishment of an Asia regional enteric fever surveillance network. The network will enable the systematic collection of data in order to fill knowledge gaps on the impact of severe typhoid and paratyphoid — diseases collectively referred to as enteric fever.

Axel Hoos, MD, PhD, Appointed as Interim Chairman of the Sabin Board of Trustees

WASHINGTON, D.C. — December 10, 2014 — The Sabin Vaccine Institute (Sabin) today announced that its Board of Trustees unanimously appointed Axel Hoos, MD, PhD, to serve as the interim Chairman of the Board. Building upon the past successes of late Chairman Morton P. Hyman, Dr. Hoos will be instrumental to providing continuity to the institute and to Sabin’s efforts in launching new programs, clinical trials and advocacy campaigns around the world.

Announcement of U.S. Science Envoys

Washington, DC - December 4, 2014 Four eminent scientists have agreed to serve as U.S. Science Envoys beginning in January, 2015: Dr. Peter Hotez, Dr. Jane Lubchenco, Dr. Arun Majumdar, and Dr. Geri Richmond. Announced by President Obama in Cairo in June 2009, the U.S. Science Envoy program demonstrates the United States’ commitment to science, technology, and innovation as tools of diplomacy and economic growth.

Statement by Amb. Michael Marine, CEO of the Sabin Vaccine Institute, on the Passing of Morton P. Hyman

Morton P. Hyman, a renowned philanthropic and public health leader and Chariman of the Sabin Vaccine Institute Board of Trustees, passed away peacefully yesterday surrounded by his family and loved ones. The following is a statement from Sabin’s CEO, Ambassador Michael W. Marine, reflecting on the profound difference that Mort made during his lifetime.

Dr. Jon Andrus Named Executive Vice President of the Sabin Vaccine Institute

WASHINGTON, D.C. — September 25, 2014 — The Sabin Vaccine Institute (Sabin) today announced that effective October 17, 2014, Dr. Jon Andrus will join Sabin as Executive Vice President and Director of Vaccine Advocacy and Education. In this role, he will leverage more than three decades of experience as a global health leader with a well-documented record for fostering collaboration among national governments and partners to expand access to vaccines for the world’s poorest people.

Pages